Medications

Pomalidomide in multiple myeloma: No hints of added benefit

Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment ...

Oncology & Cancer

Blood protein EPO involved in origin and spread of cancer

Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help ...

page 6 from 15